These novel imaging biomarkers might be correlated with a panel of diagnostic, prognostic and predictive biomarkers, either immunohistochemical (ie PD‐L1), serological (ie Lactate Dehydrogenase, LDH) and molecular (ie tumor mutational burden, TMB), proposed in literature55, 56 for support the management of advanced stage melanoma patients. The gene discussed is CD274; the disease is melanoma.